Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrate
Open Access
- 26 February 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 62 (2), 558-566
- https://doi.org/10.1002/hep.27767
Abstract
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a result of mutations in ABCB11 encoding bile salt export pump (BSEP), the canalicular bile salt export pump of hepatocyte. In some PFIC2 patients with missense mutations, BSEP is not detected at the canaliculus owing to mistrafficking of BSEP mutants. In vitro, chaperone drugs, such as 4-phenylbutyrate (4-PB), have been shown to partially correct mistrafficking. Four PFIC2 patients harboring at least one missense mutation (p.G982R, p.R1128C, and p.T1210P) were treated orally with 4-PB and followed prospectively. Patient mutations were reproduced in a Bsep/green fluorescent protein plasmid. Cellular localization of the resulting Bsep mutants was studied in a hepatocellular line (Can 10), and effects of treatment with 4-PB and/or ursodeoxycholic acid (UDCA) were assessed. In Can 10 cells, Bsep mutants were detected in the endoplasmic reticulum instead of at the canalicular membrane. Treatment with 4-PB and UDCA partially corrected Bsep mutant targeting. With 4-PB, we observed, in all patients, a decrease of pruritus and serum bile acid concentration (BAC) as well as an improvement of serum liver tests. Pathological liver injuries improved, and BSEP, which was not detected at the canalicular membrane before treatment, appeared at the canalicular membrane. Bile analyses showed an increase in BAC with 4-PB. Patient conditions remained stable with a median follow-up of 40 months (range, 3-53), and treatment tolerance was good. Conclusion: 4-PB therapy may be efficient in selected patients with PFIC2 owing to ABCB11 missense mutations affecting BSEP canalicular targeting. Bile secretion improvement may be a result of the ability of 4-PB to retarget mutated BSEP. (Hepatology 2015) Hepatology 2015;62:558–566Keywords
This publication has 28 references indexed in Scilit:
- ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): Phenotypic differences between PFIC1 and PFIC2 and natural historyJournal of Hepatology, 2010
- Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicingJournal of Hepatology, 2008
- Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type IIJournal of Hepatology, 2008
- Severe Bile Salt Export Pump Deficiency: 82 Different ABCB11 Mutations in 109 FamiliesGastroenterology, 2008
- Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseasesAmerican Journal of Physiology-Cell Physiology, 2007
- 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumpsJournal of Hepatology, 2007
- The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type IIJCI Insight, 2002
- Long-Term Treatment with Sodium Phenylbutyrate in Ornithine Transcarbamylase-Deficient PatientsMolecular Genetics and Metabolism, 2001
- In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.JCI Insight, 1997